Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK
US8785429B2 · kind B2 · utility
0Cited by
8References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 6, 2013 |
| Grant date | Jul 22, 2014 |
| Priority date | — |
| Expiry date | Mar 6, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are JAK inhibitors of formula Iwhere G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.